Cover Image
市場調查報告書

法朗西斯菌(Francisella)的開發中產品分析

Francisella Tularensis Infections - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 255963
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
法朗西斯菌(Francisella)的開發中產品分析 Francisella Tularensis Infections - Pipeline Review, H2 2015
出版日期: 2015年08月26日 內容資訊: 英文 45 Pages
簡介

法朗西斯菌(Francisella)是造成兔熱病的革蘭氏陰性菌的病原性種。法朗西斯菌(Francisella)是有偏向性·條件性的細胞內細菌,其成長需要半胱胺酸。兔熱病是可能嚴重化的疾病,會併發肺炎、胸痛、血痰等,甚至嚴重到陷入呼吸困難,導致停止呼吸。

本報告提供治療全球各國的法朗西斯菌(Francisella)用的開發中產品之開發情形相關分析,提供開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

法朗西斯菌(Francisella)概要

治療藥的開發

  • 法朗西斯菌(Francisella)開發中產品:概要
  • 法朗西斯菌(Francisella)開發中產品:比較分析

各企業開發中的法朗西斯菌(Francisella)治療藥

大學/研究機關研究中的法朗西斯菌(Francisella)治療藥

開發中產品的概要

  • 初期階段的產品

法朗西斯菌(Francisella)治療藥:開發中的產品一覽(各企業)

法朗西斯菌(Francisella)治療藥:研究中的產品一覽(大學/研究機關別)

法朗西斯菌(Francisella)治療藥的的開發企業

  • Aradigm Corporation
  • EpiVax, Inc.
  • Evolva SA
  • Tetraphase Pharmaceuticals Inc.

法朗西斯菌(Francisella):治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • ciprofloxacin hydrochloride
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展情形
  • EV-009
  • francisella tularensis strain SchuS4 vaccine
  • francisella tularensis vaccine
  • Monoclonal Antibodies to Inhibit EF-Tu for Francisella Tularensis Infections
  • Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections
  • Small Molecules to Inhibit FtsZ Protein for Bacterial Infections
  • Small Molecules to Inhibit InhA for Infectious Diseases
  • Small Molecules to Inhibit Nucleolin for Oncology and Infectious Disease
  • SRI-011225
  • TP-271
  • tularemia vaccine
  • TuliVax
  • Francisella Tularensis Infections

法朗西斯菌(Francisella)治療藥:最新的藥物簡介

法朗西斯菌(Francisella)治療藥:開發暫停的產品

法朗西斯菌(Francisella)治療藥:開發中止的產品

法朗西斯菌(Francisella)相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6998IDB

Summary

Global Markets Direct's, 'Francisella Tularensis Infections - Pipeline Review, H2 2015', provides an overview of the Francisella Tularensis Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Francisella Tularensis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Francisella Tularensis Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Francisella Tularensis Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Francisella Tularensis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Francisella Tularensis Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Francisella Tularensis Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Francisella Tularensis Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Francisella Tularensis Infections Overview
  • Therapeutics Development
    • Pipeline Products for Francisella Tularensis Infections - Overview
    • Pipeline Products for Francisella Tularensis Infections - Comparative Analysis
  • Francisella Tularensis Infections - Therapeutics under Development by Companies
  • Francisella Tularensis Infections - Therapeutics under Investigation by Universities/Institutes
  • Francisella Tularensis Infections - Pipeline Products Glance
    • Early Stage Products
  • Francisella Tularensis Infections - Products under Development by Companies
  • Francisella Tularensis Infections - Products under Investigation by Universities/Institutes
  • Francisella Tularensis Infections - Companies Involved in Therapeutics Development
    • Aradigm Corporation
    • Arno Therapeutics, Inc.
    • EpiVax, Inc.
    • Tetraphase Pharmaceuticals Inc.
  • Francisella Tularensis Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ciprofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • francisella tularensis [strain SchuS4] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRI-011225 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tularemia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TuliVax - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Francisella Tularensis Infections - Recent Pipeline Updates
  • Francisella Tularensis Infections - Dormant Projects
  • Francisella Tularensis Infections - Dormant Projects
  • Francisella Tularensis Infections - Discontinued Products
  • Francisella Tularensis Infections - Product Development Milestones
    • Featured News & Press Releases
      • May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
      • Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
      • Oct 19, 2011: Tetraphase Receives NIAID Contract Worth Upto $36m For Development Of TP-271
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Francisella Tularensis Infections, H2 2015
  • Number of Products under Development for Francisella Tularensis Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Francisella Tularensis Infections - Pipeline by Aradigm Corporation, H2 2015
  • Francisella Tularensis Infections - Pipeline by Arno Therapeutics, Inc., H2 2015
  • Francisella Tularensis Infections - Pipeline by EpiVax, Inc., H2 2015
  • Francisella Tularensis Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Francisella Tularensis Infections Therapeutics - Recent Pipeline Updates, H2 2015
  • Francisella Tularensis Infections - Dormant Projects, H2 2015
  • Francisella Tularensis Infections - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Francisella Tularensis Infections, H2 2015
  • Number of Products under Development for Francisella Tularensis Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top